Company Description
Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia.
It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy.
The company’s lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome.
Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.
| Country | Sweden |
| Founded | 2004 |
| IPO Date | Jun 5, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 217 |
| CEO | Renee Aguiar-Lucander |
Contact Details
Address: Kungsbron 1, D5 Stockholm, 111 22 | |
| Phone | 46 84 11 30 05 |
| Website | calliditas.se |
Stock Details
| Ticker Symbol | CALT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| IPO Price | $19.50 |
| CIK Code | 0001795579 |
| CUSIP Number | 13124Q106 |
| ISIN Number | US13124Q1067 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Renee Aguiar-Lucander | Chief Executive Officer |
| Fredrik Johansson | Chief Financial Officer |
| Lars Stubberud | Vice President of Technical Operations |
| Asa Hillsten | Head of IR and Sustainability |
| Brian Gorman | Group General Counsel |
| Sandra Frithiof | Vice President of Human Resources |
| Ann-Kristin Myde BSc | Head of Clinical Development and Vice President of Project Management |
| Dr. Richard S. Philipson M.D. | Chief Medical Officer |
| Teona Johnson | Head of US Marketing |
| David Ferraro | Head of US Sales |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 23, 2024 | 15F-12B | Filing |
| Sep 23, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Sep 20, 2024 | 25-NSE | Filing |
| Sep 18, 2024 | SC TO-T/A | Filing |
| Sep 18, 2024 | SC 14D9/A | Filing |
| Sep 17, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Sep 16, 2024 | EFFECT | Notice of Effectiveness |
| Sep 16, 2024 | SC TO-T/A | Filing |
| Sep 13, 2024 | 25 | Filing |
| Sep 13, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |